EPEleni A. Papadopoulos

Eleni A. Papadopoulos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eleni A. Papadopoulos has a total of 62 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Maternal exposure to sleep aids and risk of specific birth defects in the Birth Defects Study To Evaluate Pregnancy exposureS

    by Meredith M Howley, Martha M Werler, Melissa Tracy, Eva M Williford, Eleni A Papadopoulos, Elizabeth C Ailes, Jennita Reefhuis, Sarah C Fisher

    Study Objectives: Insomnia symptoms are often reported during pregnancy, prompting use of pharmacologic treatments. We explored associations between treatments used during the month before through the third month of pregnancy (“early pregnancy”) and risk of birth defects using Birth Defects Study to Evaluate Pregnancy exposureS (BD-STEPS) data from 2014-2021. Methods: Pregnancies affected by birth defects (“cases”) were identified from surveillance systems in seven states; liveborn infants without birth defects (“controls”) were randomly selected from the same catchment areas. Mothers of cases and controls reported early pregnancy exposures via interview, including use of prescription, over-the-counter, or herbal sleep aids. For defects with ≥5 exposed cases, we used Firth’s logistic regression to estimate propensity score-adjusted odds ratios (aORs) and 95% confidence intervals (CIs), adjusting for maternal age, race/ethnicity, education, body mass index, previous live birth, history of depression/anxiety, early pregnancy use of antipsychotics, anxiolytics, antidepressants, opioids, cigarettes, alcohol, and prenatal vitamins, occurrence of stressful events, occupation outside the home, health insurance, and site. Results: Overall, 237 (7%) cases and 140 (8%) controls reported early pregnancy sleep aid use. We calculated aORs for 12/22 defects, which ranged from 0.52 for d-transposition of the great arteries to 1.61 for coarctation of the aorta. All CIs included the null. Conclusions: Results suggest sleep aids do not increase risk of most defects studied, but increased risk for coarctation of the aorta cannot be ruled out. Small numbers limited analyses. Studies examining the severity of underlying sleep disorders and impacts of specific sleep aids would be beneficial.

  • Neighborhood deprivation and the risk of stillbirth in New York

    by Eva M Williford, Heater Aydin-Ghormoz, Sarah C Fisher, Eleni A Papadopoulos, Melissa Tracy, Meredith M Howley

    Stillbirth (fetal death ≥ 20 weeks gestation) occurs in approximately 21,000 births each year in the United States. Previous studies have observed associations between neighborhood deprivation and adverse perinatal outcomes. We estimated associations between neighborhood deprivation and singleton stillbirth in New York. We performed a cross-sectional study of stillbirths and live births from hospital claims data from the Statewide Planning and Research Cooperative System (2022-2024). Neighborhood deprivation index (NDI) at the census tract level was assigned to geocoded addresses at delivery. Risk ratios (RR) and 95% confidence intervals (CIs) were estimated using a generalized estimating equations model adjusted for individual-level maternal variables of age at delivery, race/ethnicity, marital status, and primary health insurance payer. Our analysis included 3,128 stillbirths and 552,361 live births. The NDI quartiles were associated with stillbirth, with higher levels of deprivation corresponding to increased risk compared to the least deprived quartiles. We observed the highest risk of stillbirth among women in the most deprived quartile (RR 1.42; 95% CI 1.25-1.61). The association of NDI quartile on the risk of stillbirth did not differ by race/ethnicity. Our findings highlight that women residing in the most deprived NDI quartile could benefit from enhanced prenatal services and support.

  • Open Access

    Maternal Stressors and Social Support in Early Pregnancy and the Risk of Stillbirth Among Fetuses With Birth Defects: Exploring Effect Modification by Race/Ethnicity

    by Meredith M. Howley, Jada M. Scott, Eva M. Williford, Uma M. Reddy, Eleni A. Papadopoulos, Suzan L. Carmichael, Chris M. Cunniff, A. J. Agopian, Nahed Elhassan, Wendy N. Nembhard, et al.

    Background: Prenatal stress and social support are associated with adverse birth outcomes, including stillbirth, in the general population. Their relationship to stillbirth among fetuses with birth defects is unclear. Using data from the National Birth Defects Prevention Study and the Birth Defects Study To Evaluate Pregnancy exposureS, we examined associations between maternal stress and social support and the risk of stillbirth among fetuses with birth defects and whether these associations differed by maternal race/ethnicity. Methods: Participants self‐reported exposure to stressors and social supports experienced 3 months before conception through the first trimester. Using log‐binomial models, we estimated relative risks (RR) and 95% confidence intervals (CI) of stillbirth associated with high stress and low social support, adjusting for maternal age and race/ethnicity. We assessed additive and multiplicative effect measure modification by maternal race/ethnicity. Results: Neither stress nor social support was associated with stillbirth among fetuses with birth defects. Although we did not observe interaction, we observed increased risk of stillbirth among non‐Hispanic Black women with low stress (RR = 2.1, 95% CI = 1.3–3.6), Hispanic women with low stress (1.4, 1.0–2.1), and non‐Hispanic Black women with high stress (2.8, 1.4–5.2) compared to non‐Hispanic White women with low stress. We observed a similar pattern of results for low social support. Conclusions: Stress and social support were not associated with stillbirth in fetuses with birth defects. We observed elevated risk of stillbirth among non‐Hispanic Black women regardless of stress and social support levels.

  • Maternal psychosocial stress and social support and stillbirth

    by Eva M. Williford, Eleni A. Papadopoulos, Sarah C. Fisher, Uma M. Reddy, Elizabeth C. Ailes, Mahsa Yazdy, Eirini Nestoridi, Wes Duke, Wendy N. Nembhard, Meredith M. Howley

  • Patterns of Yeast Infections and Antifungal Use in the First Trimester of Pregnancy: Findings from the Birth Defects Study to Evaluate Pregnancy exposureS, 2014–2019

    by Eleni A. Papadopoulos, Meredith M. Howley, Sarah C. Fisher, Martha M. Werler, Paul A. Romitti, Marilyn L. Browne

    Background: Yeast infections are common during pregnancy. Understanding their current prevalence and corresponding treatments during pregnancy is important. We used data from a U.S. population-based retrospective study of recently pregnant people to describe patterns of first trimester maternal yeast infections and antifungal use. Materials and Methods: Using a cohort of control participants from the Birth Defects Study to Evaluate Pregnancy exposureS, self-reports of first trimester yeast infections and antifungal use were collected via computer-assisted telephone interviews for births during 2014–2019. We described maternal characteristics and examined the prevalence of yeast infections and antifungal use overall and by study site and birth year. Tests for trend were used to evaluate changes over the study period. Results: After exclusions, there were 1,524 control participants included in our sample. First trimester yeast infections (9.8%) and antifungal use (8.6%) were common. More participants reported prescription (52.7%) than over-the-counter (45.0%) antifungals; most users reported a topical antifungal (72.5%). Prevalence of yeast infections and antifungal use increased modestly, but nonsignificantly, over the study period, ranging from 7.8% to 10.9% for yeast infections and 7.2% to 9.8% for antifungal use. Prevalence of topical and over-the-counter antifungals significantly increased over the study period; use of oral and prescription antifungals modestly decreased. Conclusions: In our cohort, first trimester yeast infections and antifungal use were relatively common and modestly increased throughout the study period, although this trend was not significant. We observed significant increases for topical and over-the-counter antifungals. Additional research is needed to investigate the reasons behind these prevalence changes.

  • Antifungal medication use during early pregnancy and the risk of congenital heart defects in the National Birth Defects Prevention Study, 1997–2011

    by Eleni A. Papadopoulos, Meredith M. Howley, Sarah C. Fisher, Alissa R. Van Zutphen, Martha M. Werler, Paul A. Romitti, Marilyn L. Browne, for the National Birth Defects Prevention Study

    Background: Fungal infections are common among pregnant people. Recent studies suggest positive associations between oral antifungals used to treat fungal infections and congenital heart defects (CHDs).Methods: We estimated associations between first trimester antifungal use and 20 major, specific CHDs using data from the National Birth Defects Prevention Study (NBDPS), a multi‐site, case–control study that included pregnancies with estimated delivery dates from October 1997 through December 2011. Infants with CHDs (“cases”) were ascertained from 10 birth defect surveillance programs. Live born infants without major birth defects (“controls”) were randomly selected from birth records or hospital discharge lists. First trimester antifungal use was self‐reported via maternal interview. We estimated adjusted odds ratios (AORs) and 95% confidence intervals (CIs) using logistic regression with Firth's penalized likelihood.Results: First trimester antifungal use was reported by 148/11,653 (1.3%) case and 123/11,427 (1.1%) control participants. We estimated AORs for 12 CHDs; six had AORs >1.5 (tetralogy of Fallot, double outlet right ventricle with transposition of the great arteries [DORV‐TGA], atrioventricular septal defect, hypoplastic left heart syndrome, pulmonary atresia, muscular ventricular septal defect), and one (pulmonary valve stenosis) had an AOR <0.7. All CIs included the null, except for DORV‐TGA.Conclusions: First trimester antifungal use was rare. We observed some positive associations for several specific CHDs in our analysis, although the CIs largely included the null. Results do not support a large increase in risk, but smaller increases in risk for certain CHD cannot be ruled out.


  • Antifungal medication use during pregnancy and the risk of selected major birth defects in the National Birth Defects Prevention Study, 1997–2011

    by Eleni A. Papadopoulos, Meredith M. Howley, Sarah C. Fisher, Alissa R. Van Zutphen, Martha M. Werler, Paul A. Romitti, Marilyn L. Browne, for the National Birth Defects Prevention Study

    Purpose: Recent studies suggest increased birth defect risk associated with maternal use of specific oral antifungals. We estimated associations between first‐trimester antifungal use and selected non‐cardiac birth defects using National Birth Defects Prevention Study (NBDPS) data.Methods: Participants with a pregnancy affected by a study‐eligible birth defect (“cases”) were ascertained from 10 birth defect surveillance programs; participants who delivered livebirths without a major birth defect (“controls”) were randomly selected from birth records or hospital discharge lists. First‐trimester antifungal use was self‐reported via maternal interview. We estimated adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for birth defects with ≥5 exposed cases using logistic regression. We estimated crude ORs and exact 95% CIs for birth defects with 3–4 exposed cases. Additionally, we conducted a probabilistic bias analysis of exposure misclassification.Results: Our analysis included 19 624 cases and 11 427 controls; 257 (1.3%) cases and 123 (1.1%) controls reported first‐trimester antifungal use. Of those who reported antifungals, 62.6% of cases and 64.2% of controls reported topical antifungals; 10.1% of cases and 4.9% of controls reported oral antifungals. We observed the strongest associations for encephalocele and Dandy‐Walker malformation and modestly elevated estimates for several other defects. Bias‐adjusted estimates were similar to the main analysis.Conclusion: First‐trimester antifungal use was positively associated with several birth defects in our analysis, although CIs were imprecise. Further study is warranted to investigate associations between antifungal use and birth defects, including potential bias due to confounding by indication.


  • Open Access

    Influenza vaccination during pregnancy and risk of selected major structural congenital heart defects, National Birth Defects Prevention Study 2006–2011

    by Kristin Palmsten, Jonathan Suhl, Kristin M. Conway, Elyse O. Kharbanda, Thomas D. Scholz, Elizabeth C. Ailes, Janet D. Cragan, Eirini Nestoridi, Eleni A. Papadopoulos, Stephen M. Kerr, et al.

    Background: Although results from studies of first‐trimester influenza vaccination and congenital heart defects (CHDs) have been reassuring, data are limited for specific CHDs.Methods: We assessed associations between reported maternal influenza vaccination, 1 month before pregnancy (B1) through end of third pregnancy month (P3), and specific CHDs using data from a multisite, population‐based case–control study. Analysis included 2,982 case children diagnosed with a simple CHD (no other cardiac involvement with or without extracardiac defects) and 4,937 control children without a birth defect with estimated delivery dates during 2006–2011. For defects with ≥5 exposed case children, we used logistic regression to estimate propensity score‐adjusted odds ratios (aORs) and 95% confidence intervals (CIs), adjusting for estimated delivery year and season; plurality; and maternal age at delivery, race/ethnicity, low folate intake, and smoking and alcohol use during B1P3.Results: Overall, 124 (4.2%) simple CHD case mothers and 197 (4.0%) control mothers reported influenza vaccination from 1 month before through the third pregnancy month. The aOR for any simple CHD was 0.97 (95% CI: 0.76–1.23). Adjusted ORs for specific simple CHDs ranged from 0.62 for hypoplastic left heart syndrome to 2.34 for total anomalous pulmonary venous return (TAPVR). All adjusted CIs included the null except for TAPVR.Conclusions: Although we cannot fully exclude that exposure misclassification may have masked risks for some CHDs, findings add to existing evidence supporting the safety of inactivated influenza vaccination during pregnancy. The TAPVR result may be due to chance, but it may help inform future studies.


  • Interaction of maternal medication use with ambient heat exposure on congenital heart defects in the National Birth Defects Prevention Study

    by Yanqiu Ou, Eleni A. Papadopoulos, Sarah C. Fisher, Marilyn L. Browne, Ziqiang Lin, Aida Soim, Yi Lu, Scott Sheridan, Jennita Reefhuis, Peter H. Langlois, et al.


  • Maternal exposure to heparin products and risk of birth defects in the National Birth Defects Prevention Study

    by Meredith M. Howley, Sarah C Fisher, Alissa R Van Zutphen, Eleni A. Papadopoulos, Jenil Patel, Angela E. Lin, Marilyn L. Browne

    Background: Heparin and low‐molecular‐weight heparin are the preferred anticoagulants during pregnancy as they do not cross the placenta. Although research on the safety of heparin products has been reassuring, previous studies have considered birth defects as a single outcome or by larger organ system and have not examined associations with specific birth defects.Methods: We analyzed data from the National Birth Defects Prevention Study, a multisite, population‐based case–control study from 1997 to 2011. We used unconditional logistic regression with Firth's penalized likelihood to calculate adjusted odds ratios (ORs) and profile likelihood 95% confidence intervals (CIs) for defects with at least five exposed cases. For defects with 3–4 exposed cases, we estimated crude ORs and exact 95% CIs.Results: Of the 42,743 women in our analysis, 117 (0.4%) case and 44 (0.4%) control mothers reported using a heparin product in early pregnancy. The adjusted ORs ranged from 0.9 to 3.9 and were elevated for anorectal atresia (OR = 2.0, 95% CI = 0.8–4.3), longitudinal limb deficiency (3.5, 1.3–7.8), transverse limb deficiency (1.8, 0.6–4.3), atrioventricular septal defect (3.9, 1.4–9.0), and secundum atrial septal defect (2.2, 1.2–3.8).Conclusions: We observed elevated associations for some birth defects, although heparin is a rare exposure, which limited our ability to evaluate many associations. Future studies that can explore specific birth defects and adequately control for confounding by indication are needed. Given that women with an indication for heparin products during pregnancy often need to take medication, one must remain mindful of the underlying risk of a birth defect that exists regardless of medication use.